|
1
|
Oliai C, Lanciano R, Sprandio B, Yang J,
Lamond J, Arrigo S, Good M, Mooreville M, Garber B and Brady LW:
Stereotactic body radiation therapy for the primary treatment of
localized prostate cancer. J Radiat Oncol. 2:63–70. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang YY, Wang YS, Liu T, Yang K, Yang GQ,
Liu HC, Wang SS and Yang JL: Efficacy study of CyberKnife
stereotactic radiosurgery combined with CIK cell immunotherapy for
advanced refractory lung cancer. Exp Ther Med. 5:453–456.
2013.PubMed/NCBI
|
|
3
|
Sharma S, Ott J, Williams J and Dickow D:
Dose calculation accuracy of the Monte Carlo algorithm for
CyberKnife compared with other commercially available dose
calculation algorithms. Med Dosim. 36:347–350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang YS, Wang YY, Jiang P, Ma JJ, Qu Z,
Wang XL, Li JT and Jia XF: Short-term outcomes of CyberKnife
therapy for advanced high-risk tumors: A report of 160 cases. Exp
Ther Med. 3:725–727. 2012.PubMed/NCBI
|
|
5
|
Meng MB, Zaorsky NG, Jiang C, Tian LJ,
Wang HH, Liu CL, Wang J, Tao Z, Sun Y, Wang J, Pang QS, Zhao LJ,
Yuan ZY and Ping W: Radiotherapy and chemotherapy are associated
with improved outcomes over surgery and chemotherapy in the
management of limited-stage small cell esophageal carcinoma.
Radiother Oncol. 106:317–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang X, Wang YY, Jiang P, Ma JJ, Qu Z, Liu
HC, Wang SS and Wang YS: Clinical application of CyberKnife for
high-risk central nervous system tumors: A clinical trial report of
60 cases. Exp Ther Med. 3:105–108. 2012.PubMed/NCBI
|
|
7
|
Lin MC, Chen CM, Tseng HM, Xiao F and
Young YH: A proposed method to comprehensively define outcomes in
acoustic tumor patients undergoing CyberKnife management.
Stereotact Funct Neurosurg. 91:177–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Mamgani A, Rooij Pv, Tans L, Verduijn
GM, Sewnaik A and de Jong RJ: A prospective evaluation of
patient-reported quality-of-life after (chemo)radiation for
oropharyngeal cancer: which patients are at risk of significant
quality-of-life deterioration? Radiother Oncol. 106:359–363. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohguri T, Imada H, Narisada H, Yahara K,
Morioka T, Nakano K, Miyaguni Y and Korogi Y: Systemic chemotherapy
using paclitaxel and carboplatin plus regional hyperthermia and
hyperbaric oxygen treatment for non-small cell lung cancer with
multiple pulmonary metastases: preliminary results. Int J
Hyperthermia. 25:160–167. 2009. View Article : Google Scholar
|
|
10
|
Shen H, Li XD, Wu CP, Yin YM, Wang RS and
Shu YQ: The regimen of gemcitabine and cisplatin combined with
radiofrequency hyperthermia for advanced non-small cell lung
cancer: a phase II study. Int J Hyperthermia. 27:27–32. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He B, Wang X, Shi HS, Xiao WJ, Zhang J, Mu
B, Mao YQ, Wang W and Wang YS: Quercetin liposome sensitizes colon
carcinoma to thermotherapy and thermochemotherapy in mice models.
Integr Cancer Ther. 12:264–270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abiko T, Kawamura M, Izumi Y, Oyama T,
Saito Y and Kobayashi K: Prediction of anti-tumour effect of
thermochemotherapy with in vitro thermochemosensitivity testing for
non-small cell lung cancer. Int J Hyperthermia. 23:267–275. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Collins RH Jr, Shpilberg O, Drobyski WR,
Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W,
Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH and
Nemunaitis J: Donor leukocyte infusions in 140 patients with
relapsed malignancy after allogeneic bone marrow transplantation. J
Clin Oncol. 15:433–444. 1997.PubMed/NCBI
|
|
14
|
Wang YF, Kunda PE, Lin JW, Wang H, Chen
XM, Liu QL and Liu T: Cytokine-induced killer cells co-cultured
with complete tumor antigen-loaded dendritic cells, have enhanced
selective cytotoxicity on carboplatin-resistant retinoblastoma
cells. Oncol Rep. 29:1841–1850. 2013.
|
|
15
|
Linn YC and Hui KM: Cytokine-induced
killer cells: NK-like T cells with cytotolytic specificity against
leukemia. Leuk Lymphoma. 44:1457–1462. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, He M, Shi W, Sha H, Feng J, Wang S
and Wang Y: Inducible costimulator (ICOS) enhances the cytolytic
activity of cytokine-induced killer cells against gallbladder
cancer in vitro and in vivo. Cancer Invest. 27:244–250. 2009.
View Article : Google Scholar : PubMed/NCBI
|
